Results 101 to 110 of about 932,507 (267)
Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more sourcePARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi +13 morewiley +1 more sourceLDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber +13 morewiley +1 more sourcePlecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor +10 morewiley +1 more sourceSearch for Physics beyond the Standard Model at NA62 [PDF]
R. Fiorenza, A. Akmete, R. Aliberti, F. Ambrosino, Roberto Ammendola, B. Angelucci, A. Antonelli, G. Anzivino, R. Arcidiacono, M. U. Ashraf, T. Bache, A. Baeva, D. Baigarashev, L. Bandiera, M. Barbanera, V. Bautin, J. Bernhard, A. Biagioni, L. Bician, C. Biino, A. Bizzeti, T. Blazek, B. Bloch-Devaux, P. Boboc, Vincenzo Bonaiuto, M. Boretto, M. Bragadireanu, A. Briano Olvera, D. Britton, F. Brizioli, M. B. Brunetti, D. Bryman, F. Bucci, N. Canale, T. Capussela, J. Carmignani, A. Ceccucci, P. Cenci, M. Ceoletta, V. Cerny, C. Cerri, X. Chang, B. Checcucci, A. Conovaloff, P. S. Cooper, E. Cortina, M. Corvino, F. Costantini, A. Cotta Ramusino, D. H. Coward, Paolo Cretaro, G. D’Agostini, J.B. Dainton, P. Dalpiaz, H. Danielsson, B. De Martino, M. D’Errico, N. De Simone, D. Di Filippo, L. Di Lella, N. Doble, B. Dobrich, F. Duval, V. Duk, D. Emelyanov, J. Engelfried, T. Enik, N. Estrada-Tristan, V. Falaleev, R. Fantechi, V. Fascianelli, L. Federici, S. Fedotov, A. Filippi, R. Fiorenza, M. Fiorini, M. Francesconi, Ottorino Frezza, J. R. Fry, Jie Fu, A. Fucci, L. Fulton, E. Gamberini, L. Gatignon, G. Georgiev, S. A. Ghinescu, A. Gianoli, R. Giordano, M. Giorgi, S. Giudici, F. Gonnella, K. Gorshanov, E. Goudzovski, C. Graham, R. Guida, E. Gushchin, F. Hahn, H. F. Heath, J. Henshaw, Z. Hives +99 moreopenalex +1 more sourcePeroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski +17 morewiley +1 more sourceCrucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples
Molecular Oncology, EarlyView.This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel +10 morewiley +1 more sourceDammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh +8 morewiley +1 more source
